Six-Year Efficacy of Novartis Kesimpta® in Newly Diagnosed Relapsing MS Patients
Novartis has unveiled findings from the ALITHIOS open-label extension study, spotlighting the enduring effectiveness of continuous Kesimpta® (ofatumumab) treatment for up to six years in individuals recently diagnosed with relapsing…
AstraZeneca Pioneers Advances in Infectious Disease Protection at ECCMID 2024
AstraZeneca is gearing up to present a wealth of new clinical, real-world, and early science data encompassing its Vaccines & Immune Therapies portfolio at the 34th European Congress of Clinical…
Alert: Falsified (Contaminated) USP/EP Propylene Glycol – Medical Product Alert N°1/2024
Alert Overview This alert from the World Health Organization (WHO) addresses the discovery of falsified DOW USP/EP Propylene Glycol in Pakistan. Authentic DOW USP/EP Propylene Glycol is a crucial raw…
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
Viatris, a leading global healthcare company, has announced the appointment of Corinne Le Goff as its Chief Commercial Officer, effective immediately. Le Goff brings over 25 years of experience in…
WuXi Biologics Chosen for S&P Global Sustainability Yearbook 2024
WuXi Biologics, known as WuXi Bio (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announces its selection for the prestigious S&P Global Sustainability Yearbook 2024 (“Yearbook”)…
Labcorp Unveils Groundbreaking Blood Test for Early Detection of Neurodegenerative Diseases and Brain Injuries
Labcorp, a leading provider of innovative laboratory services globally, has announced the launch of the nation’s inaugural glial fibrillary acidic protein (GFAP) test. This test serves as a pivotal blood-based…
FDA Approves TEVIMBRA® for Advanced Esophageal Cancer Post-Chemotherapy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) has received FDA approval for TEVIMBRA® (tislelizumab-jsgr) as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC)…
Novartis’ Fabhalta® (iptacopan) reduces proteinuria by 38.3% in IgA Nephropathy Patients
Novartis recently shared promising findings from the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), a Factor B inhibitor targeting the alternative complement pathway, in patients with IgA nephropathy (IgAN). In…
Unveiling the Growing Impact of Chronic Kidney Disease on Patients, the Environment, and Economies
A recent modeling analysis conducted by AstraZeneca, named IMPACT CKD, projects that by 2032, up to 16.5% of the population across eight countries will be afflicted by chronic kidney disease…
Modalis Announces Partnership with Ginkgo Bioworks
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable…
Agenus Reveals Latest Phase 1 Findings and Advances in BOT/BAL Development for Metastatic MSS Colorectal Cancer
Agenus Inc. (NASDAQ: AGEN), a renowned player in the realm of discovering and advancing novel immunological treatments for diverse cancers, has disclosed the latest outcomes from its Phase 1 clinical…
Revance Unveils Latest DAXXIFY® Findings at the 2024 American Academy of Neurology Annual Conference
Revance Therapeutics, Inc. (NASDAQ: RVNC) has unveiled significant insights into DAXXIFY® for the treatment of cervical dystonia at the American Academy of Neurology (AAN) annual meeting, running from April 13-18,…